FDA Hepatitis Update - FDA briefing on boceprevir and telaprevir - follow up

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Hepatitis Update - FDA briefing on boceprevir and telaprevir - follow up

	 You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

If you are experiencing problems with any of the links on the previous message regarding the FDA briefing on boceprevir and telaprevir, please use the links available at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256712.htm.

Apologies for any inconvenience.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420